Claims for Patent: 10,525,115

Summary for Patent: 10,525,115

Title:	Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
Abstract:	The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Inventor(s):	Rammensee; Hans-Georg (Unterjesingen, DE), Stevanovic; Stefan (Tuebingen, DE), Walz; Juliane (Tuebingen, DE), Kowalewski; Daniel Johannes (Tuebingen, DE), Berlin; Claudia (Tuebingen, DE)
Assignee:	Immatics Biotechnologies GmbH (Tuebingen, DE)
Application Number:	16/370,250
Patent Claims:	1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that selectively recognize cells, which present a peptide consisting of the amino acid sequence SEQ ID NO: 35, wherein the peptide is in a complex with an MHC molecule, wherein said cancer is selected from acute myeloid leukemia, chronic lymphatic leukemia, renal cell carcinoma, and non-small cell lung carcinoma. 2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, wherein the activated T cells are expanded in vitro. 6. The method of claim 1, wherein the MHC molecule is a class I or II MHC molecule. 7. The method of claim 1, wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MHC molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells. 8. The method of claim 7, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. 9. The method of claim 8, wherein the antigen presenting cell is a dendritic cell or a macrophage. 10. The method of claim 5, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12. 11. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells. 12. The method of claim 1, wherein the population of activated T cells are administered in the form of a composition. 13. The method of claim 12, wherein the composition comprises at least one adjuvant. 14. The method of claim 13, wherein the at least one adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 15. The method of claim 1, wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence SEQ ID NO: 35. 16. The method of claim 15, wherein the immune response comprises a cytotoxic T cell response. 17. The method of claim 1, wherein the cancer is acute myeloid leukemia. 18. The method of claim 1, wherein the cancer is chronic lymphatic leukemia. 19. A method of treating a patient who has cancer, comprising administering to the patient a population of activated T cells that selectively recognize cells, which present a peptide consisting of the amino acid sequence SEQ ID NO: 35, wherein the peptide is in a complex with an WIC molecule, wherein said cancer is selected from acute myeloid leukemia, chronic lymphatic leukemia, renal cell carcinoma, and non-small cell lung carcinoma. 20. The method of claim 19, wherein the cancer is acute myeloid leukemia or chronic lymphatic leukemia.

Details for Patent 10,525,115

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2034-05-09